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identified and then characterized for 
the types of response that each anti-
gen elicits; this information could then 
be used to develop a component acne 
vaccine. Very few P. acnes antigens 
have been identified and studied.
It will be important to evalu-
ate the antibodies generated against 
P. acnes for other immunomodulatory 
effects, including their ability to induce 
pro inflammatory mediators and cyto-
toxicity, which might lead to tissue inju-
ry. It has been shown that some patients 
have antibodies against P. acnes, and 
positive correlations between antibody 
titers and the severity of the disease 
have been reported (Ashbee et al.,1997; 
Ingham et al.,1987; Webster et al., 
1985). Thus, not all antibodies directed 
against P. acnes may be beneficial, and 
they may even worsen the disease.
Part of the difficulty in develop-
ing any acne therapy is that there is 
no perfect animal model. Although 
the mouse model used by Nakatsuji 
et al. (2008b) demonstrated a decrease 
in ear swelling in vaccinated mice, 
the lesions produced by injection 
of P. acnes into the ears of mice do 
not reproduce clinical acne lesions 
exactly. For this reason, it is not cer-
tain that similar clinical improvement 
will occur in humans, in whom other 
varying factors, such as the presence 
of inflammatory lipids in sebum, may 
influence the growth and behavior of 
P. acnes. Nonetheless, the authors 
of this study offer an important and 
interesting concept—that focusing 
on attenuating the inflammatory 
component of the disease could be 
therapeutically beneficial. Because 
the induction of cytokines, chemo-
kines, and metalloproteinases by 
P. acnes occurs via a Toll-like receptor 2 
(TLR2)-dependent pathway, the devel-
opment of vaccines or other immune 
therapies that target TLR2 and other 
TLRs may provide other alternatives to 
conventional therapy. We are already 
familiar with agents that modulate TLR 
response, such as imiquimod, which 
enhances TLR7 and TLR8 function, 
and retinoic acid, which downregu-
lates TLR2 expression and function, 
suggesting that vaccines with potent 
anti-TLR immunity may hold promise 
for the future of acne therapy.
CONFLICT OF INTEREST
The author serves as a consultant and is on a 
scientific advisory board for Galderma, Medicis, 
Sanofi-Aventis and Stiefel.
references
Ashbee HR, Muir SR, Cunliffe WJ, Ingham E 
(1997) IgG subclasses specific to Staphylococcus 
epidermidis and Propionibacterium acnes 
in patients with acne vulgaris. Br J Dermatol 
136:730–3
Ingham E, Gowland G, Ward RM, Holland KT, 
Cunliffe WJ (1987) Antibodies to P. acnes and 
P. acnes exocellular enzymes in the normal 
population at various ages and in patients with 
acne vulgaris. Br J Dermatol 116:805–12
Kim J, Ochoa MT, Krutzik SR, Takeuchi O, 
Uematsu S, Legaspi AJ et al. (2002) Activation of 
Toll-like receptor 2 in acne triggers inflammatory 
cytokine responses. J Immunol 169:1535–41
Leyden JJ, McGinley KJ, Vowels B (1988) 
Propionibacterium acnes colonization in acne 
and non-acne. Dematology 196:55–8
Liu PT, Krutzik SR, Kim J, Modlin RL (2005) Cutting 
edge: all-trans retinoic acid down-regulates TLR2 
expression and function. J Immunol 174:2467–70
Liu PT, Phan J, Tang D, Kanchanapoomi M, Hall 
B, Krutzik SR et al. (2008) CD 209+ macrophages 
See related article on pg 2485
Germline MC1R Variants  
and BRAF Mutant Melanoma
Elke Hacker1 and Nicholas K. Hayward1
Recent studies have demonstrated that melanocortin-1 receptor (MC1R) variants 
increase the risk of melanomas harboring BRAF mutations. This finding provides 
insight into the relationship between host genotype and selection for somatic muta-
tion type. Additional larger studies are required in diverse populations to further 
examine the interaction between MC1R and BRAF in different melanoma subtypes.
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mc1r function
MC1R is a well-known G-protein-
coupled receptor found on melanocytes 
that plays an important role in the reg-
ulation of pigmentation (reviewed in 
Abdel-Malek et al., 2008). The gene is 
highly polymorphic, with more than 
60 variants documented, the major-
ity of which compromise the function 
of the receptor so that it inadequately 
responds to its ligands, α-melanocyte-
stimulating hormone (α-MSH) and 
β-defensin (Abdel-Malek et al., 2008, 
Candille et al., 2007). Variant MC1R 
isoforms affect the signal transduction 
pathways that normally result in a switch 
from pheomelanin to eumelanin pro-
duction after exposure of skin to UVR 
(Abdel-Malek et al., 2008). They are 
also strongly associated with red hair 
and freckling phenotypes (Sturm et al., 
2003), which are linked to melanoma 
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(Palmer et al., 2000). Variants have been 
classed into two groups based on the 
strength of their association with red hair 
(Sturm et al., 2003). The R variants (i.e., 
Asp84Glu, Arg151Cys, Arg160Trp, and 
Asp294His) are most highly correlated 
with red hair (mean odds ratio (OR) 
63.3, range 50.5–118.3); the r variants 
are still associated but to a lesser degree 
(mean OR 5.1, range 2.4–6.4). MC1R 
variants confer an approximately two-
fold risk of melanoma for each allele car-
ried (Palmer et al., 2000), and the effect 
remains significant even in patients who 
have a medium or dark complexion, 
suggesting that the alleles may be associ-
ated with an increased risk of melanoma 
independent of any effect on phenotype 
(Palmer et al., 2000).
Interaction between MC1R  
and BRAF mutations
In a landmark paper published in 
Science, Landi et al. (2006) sought to 
investigate whether a relationship exist-
ed between germline MC1R variants 
and somatic BRAF mutations in mela-
noma. This line of inquiry was based 
on the growing epidemiologic data 
that support the concept of divergent 
molecular pathways underlying devel-
opment of melanomas associated with 
different host and environmental risk 
factors, particularly with respect to asso-
ciated features of solar UVR exposure 
(Whiteman et al., 2003). This notion has 
been supported by molecular evidence 
that melanomas of different histotypes 
or sun-exposure histories have markedly 
different genomic aberration profiles 
and mutation frequencies of major mel-
anoma oncogenes, including BRAF and 
NRAS (Curtin et al., 2005). For example, 
melanomas arising on non-chronic sun-
damaged (non-CSD) body sites occur 
more often in younger people and have 
a high frequency of BRAF mutations. In 
contrast, melanomas from chronic sun-
damaged (CSD) sites generally occur in 
older individuals and have a lower BRAF 
mutation frequency.
Landi et al. (2006) studied melanoma 
patients from two populations: the first 
comprised 85 Italian cases drawn from 
a sample of 183 cases, all of whom 
lacked a family history of melanoma and 
had no germline mutations in INK4A, 
ARF, or CDK4. In this series, MC1R 
and BRAF data were available from 29 
CSD-associated melanomas (1 MC1R 
wild type) and 56 non-CSD melanomas 
(10 MC1R wild type). The second pop-
ulation, of 112 cases from the United 
States, comprised 54 CSD melanomas 
(11 MC1R wild type) and 58 non-CSD 
melanomas (9 MC1R wild type). Acral 
melanomas were excluded from both 
populations, solar elastosis was graded 
on an 11-point scale, and only nonsyn-
onymous variants or insertions/dele-
tions in MC1R were considered. MC1R 
genotype had no effect on the frequency 
of BRAF mutations in CSD melanomas 
in the U.S. population (n = 54), but the 
numbers were too small for such analy-
sis in the Italian population (n = 29). 
However, in non-CSD melanomas (as 
determined by the absence of solar 
elastosis in the surrounding skin), BRAF 
mutations were 6.0 and 13.2 times more 
frequent in the U.S. and Italian cases, 
respectively, that carried any MC1R 
variants than in those cases that car-
ried no variants. Cases carrying a single 
variant had 4.1 (United States) to 10.6 
(Italy) times the number of BRAF muta-
tions as individuals who were wild type 
for MC1R. In the cases carrying mul-
tiple MC1R variants, the ORs were 10.6 
(United States) and 38.6 (Italy).
This trend for increasing risk with 
higher numbers of variant MC1R alleles 
was significant (P = 0.02, United States; P 
= 0.001, Italy). It should be noted, how-
ever, that these correlations do not fully 
take into consideration the functional 
impact of the MC1R variants (i.e., R ver-
sus r). Beaumont et al. (2007) examined 
the functional impact of nine common 
MC1R variants and found that the V92M 
isoform demonstrated activity similar 
to that of the wild-type receptor. Meta-
analysis of 20 studies also showed that 
the V92M and V60L variants were not 
associated with melanoma or phenotype 
(Raimondi et al., 2008). These two vari-
ants were quite common in the Italian 
and U.S. populations studied by Landi et 
al. (2006) and Fargnoli et al. (2008).
It is important to consider the func-
tional impact of MC1R variants in 
analyses of this type. It would be inter-
esting to determine whether (as one 
would expect) R variant heterozygotes 
demonstrate a stronger association than 
r variant heterozygotes and, similarly, 
whether an increasing risk gradient exists 
across r/r, r/R, and R/R homozygotes. 
Additionally, one might consider frame-
shift variants as R variants rather than r 
variants (as they were classified here), 
because they are expected to result in 
completely nonfunctional MC1R alleles. 
Although frameshift variants are rare and 
would thus have very little impact on the 
overall published results, a reanalysis 
after recategorization is warranted.
In both populations, the BRAF–MC1R 
association was stronger in younger indi-
viduals than in those with median age of 
onset, although a test for interaction was 
not significant. In total, in non-CSD mel-
anomas BRAF mutations were present in 
6/19 (~31%) MC1R wild-type individu-
als, 45/68 MC1R heterozygotes (~66%), 
and 23/27 (~85%) MC1R homozygotes. 
In the Italian population, phenotypic 
data were available, but BRAF mutations 
were not associated with hair color, eye 
color, skin color (assessed by reflec-
tance), or tanning ability.
Because of the small sample size and 
lack of data on phenotypic character-
istics for the U.S. population, Fargnoli 
et al. (2008) subsequently combined 
the originally reported Italian popula-
tion (n = 85) with an independent set of 
cases (n = 92 for which both MC1R and 
BRAF data were available) from central 
Italy to conduct a larger, more com-
prehensive, analysis. The new patient 
sample strongly confirmed the associa-
tion between MC1R variants and BRAF-
mutant melanomas, although this time 
it was independent of chronic sun dam-
age (OR = 7.0, 95% confidence interval 
(CI) = 2.1–23.8). The authors could not 
determine the degree of solar elastosis 
in the central Italian population, so all 
melanomas were analyzed irrespec-
tive of chronic sun damage. However, 
melanomas in this study were classified 
into chronically sun-exposed body sites 
(face, scalp, neck, back of hands, lower 
legs, and forearms) and intermittently 
sun-exposed sites (chest, back, upper 
legs, and upper arms). In contrast to the 
expected findings based on their previ-
ous study (assuming there should be a 
good correlation between CSD mela-
nomas and location on chronically sun-
exposed sites), the association between 
MC1R variants and BRAF-mutant 
melanomas was greater for melanomas 
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from chronically sun-exposed sites (OR 
= 17.9, 95% CI = 2.0–157.5) than for 
those from intermittently sun-exposed 
sites (OR = 4.4, 95% CI = 1.6–12.2). 
Again, the odds of BRAF mutations 
increased as the number of MC1R vari-
ants increased (P trend = 0.01). In these 
new cases, the OR did not vary signifi-
cantly by type of MC1R variant (i.e., R 
versus r), in contrast to the previous sam-
ple (Landi et al., 2006), in which R vari-
ants were associated with a higher OR.
It is worth noting that the overall fre-
quencies of BRAF mutations in the two 
populations (63.5% in the first study 
and 43.5% in the second study) were 
significantly different (P < 0.01). When 
combining the two populations for more 
power, the MC1R–BRAF association 
was confined to BRAF-mutant mela-
nomas (OR = 7.3, 95% CI = 2.9–18.5) 
but was not affected by body site of the 
primary lesion, tumor thickness, nevus 
count, tanning ability, solar elastosis, or 
age. Although phenotypic characteristics 
were collected for both Italian popula-
tions, the association of hair or eye color 
could not be performed because of the 
limited number of patients included 
in these analyses. There is need for fur-
ther comprehensive studies to examine 
the interaction between phenotype and 
BRAF status.
Why might MC1R variants  
lead to BRAF mutations?
The reports of Landi et al. (2006) and 
Fargnoli et al. (2008) raise the question of 
why MC1R might lead to the induction 
of somatic BRAF mutations. The 
multistep model of cancer development 
predicts that cells are required to accu-
mulate multiple mutations to permit 
transformation. Mutations in differ-
ent pathways are selected for because 
they give the cell a growth advantage, 
whereas further mutations in the same 
pathway are redundant and offer no 
advantage. This concept therefore implies 
that MC1R and BRAF must function in 
distinct and largely non-overlapping 
pathways, both of which must be aber-
rant for melanomagenesis. Additionally, 
whether the link between MC1R and 
BRAF might in part be a direct conse-
quence of excess pheomelanin, which 
leads to an increase in redox stress in 
melanocytes and in turn increased DNA 
damage, warrants further investigation.
conclusions
The initial association between MC1R 
variants and BRAF mutations was con-
fined to non-CSD melanomas in Italian 
and U.S. populations; however, fur-
ther studies in an independent Italian 
population confirmed the association 
between MC1R variants and BRAF-
mutant melanomas independent of the 
degree of solar damage. Although the 
two reports provide a tantalizing insight 
into the relationship between host geno-
type and selection for type of somatic 
mutation—even when combined—the 
studies are relatively underpowered, 
as there are still small subgroup sizes 
for many of the covariates. Additional 
larger studies are required, particularly 
in other populations. A more balanced 
number of non-CSD versus CSD mela-
nomas might be useful to determine 
whether there is an effect in the latter, 
as intimated by the results of Fargnoli et 
al. (2008). Further assessment of mela-
nomas by body site and documented 
sun-exposure history would also be 
useful, as well as establishing the rela-
tionship to other variables such as pres-
ence of nonmelanoma skin cancers and 
their precursor lesions.
Moreover, if body site is to be used 
as a surrogate for non-CSD versus CSD 
melanomas (here we use the terms 
CSD and chronic sun-exposed inter-
changeably), then some discussion is 
required to determine what constitutes 
a CSD site; for example, the lower 
leg of a male indoor office worker is 
unlikely to constitute a CSD site nor 
is the scalp in an individual with thick 
long hair—both were considered CSD 
sites in these studies. Stratifying analy-
sis by histological subtypes would also 
be interesting (e.g., comparing super-
ficial spreading versus nodular versus 
lentigo maligna melanomas). More 
careful consideration of which variants 
to include as R is warranted, along with 
the derivation of better estimates of the 
effect sizes for R and r variants, as well 
as various compound heterozygous 
genotypes and individual risks associ-
ated with some of the more common 
variants. Finally, the relationship with 
NRAS and PTEN mutations should 
be explored. There is much to do, but 
resolving the above issues will further 
our understanding of melanomagenesis 
and may ultimately aid in the develop-
ment of more appropriate methods to 
prevent and treat this disease.
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